No connection

Search Results

PAVM vs YI

PAVM
PAVmed Inc.
BEARISH
Price
$9.11
Market Cap
$57.5M
Sector
Healthcare
AI Confidence
95%
YI
111, Inc.
BEARISH
Price
$6.83
Market Cap
$59.2M
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
PAVM
--
YI
--
Forward P/E
PAVM
-3.32
YI
48.79
P/B Ratio
PAVM
0.91
YI
-0.6
P/S Ratio
PAVM
810.32
YI
0.0
EV/EBITDA
PAVM
-3.78
YI
121.33

Profitability

Gross Margin
PAVM
-207.04%
YI
3.01%
Operating Margin
PAVM
-13082.7%
YI
-0.01%
Profit Margin
PAVM
564.79%
YI
-0.53%
ROE
PAVM
-32.34%
YI
-7.57%
ROA
PAVM
-39.23%
YI
-0.06%

Growth

Revenue Growth
PAVM
420.0%
YI
-26.7%
Earnings Growth
PAVM
--
YI
--

Financial Health

Debt/Equity
PAVM
0.6
YI
1.01
Current Ratio
PAVM
0.17
YI
1.09
Quick Ratio
PAVM
0.13
YI
0.45

Dividends

Dividend Yield
PAVM
--
YI
--
Payout Ratio
PAVM
0.0%
YI
0.0%

AI Verdict

PAVM BEARISH

PAVM exhibits critical financial distress, highlighted by a Piotroski F-Score of 0/9 and a catastrophic Current Ratio of 0.17, indicating a severe liquidity crisis. While revenue growth is nominally high (420%), the operational efficiency is non-existent with an operating margin of -13,082.69% and negative gross margins. There is a profound disconnect between the fundamental collapse (99.5% 5-year price decline) and the optimistic analyst target price of $40.50. The company is currently operating in a state of extreme financial fragility with no evidence of sustainable profitability.

Strengths
Significant year-over-year revenue growth (420%)
Price/Book ratio (0.91) suggests the stock is trading near its accounting book value
Recent earnings surprises have been positive relative to very low analyst expectations
Risks
Severe liquidity risk with a Current Ratio of 0.17 (cannot cover short-term obligations)
Extreme operational inefficiency evidenced by -13,082% operating margin
Negative gross margins indicate the cost of goods exceeds the selling price
YI BEARISH

YI presents a high-risk profile characterized by a stable Piotroski F-Score (5/9) that masks severe underlying fundamental decay. The most critical red flag is a negative Price/Book ratio (-0.60), indicating negative shareholders' equity and potential insolvency. This is compounded by a significant revenue contraction of -26.70% YoY and a poor Quick Ratio of 0.45, suggesting severe liquidity constraints. Despite a speculative 6-month price bounce, the lack of analyst coverage and bearish technical trend (0/100) suggest a lack of institutional support.

Strengths
Piotroski F-Score of 5/9 indicates stable short-term financial health
Operating margin is nearly at break-even (-0.01%)
Recent 6-month price recovery (+53.5%) shows speculative interest
Risks
Negative shareholders' equity as indicated by Price/Book of -0.60
Severe revenue decline (-26.70% YoY and -16.66% Q/Q)
Poor liquidity with a Quick Ratio of 0.45

Compare Another Pair

PAVM vs YI: Head-to-Head Comparison

This page compares PAVmed Inc. (PAVM) and 111, Inc. (YI) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile